{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:09:35Z","timestamp":1792706975289,"version":"4.5.0"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T00:00:00Z","timestamp":1565049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Cutaneous toxicities frequently occurred with immune checkpoint inhibitors (ICIs), although clinical and pharmacological features are incompletely characterized. The U.S. Food and Drug Administration Adverse Event Reporting System was queried to describe ICI-related cutaneous toxicities, focusing on severe cutaneous adverse reactions (SCARs): Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. As compared with other anticancer drugs, a higher proportion of death (11.3% vs. 8.7%) and serious reports (42.7% vs. 34.6%) emerged for ICIs (p &amp;lt; .05). A higher frequency of coreported allopurinol and antiepileptics was recorded among 2,525 total SCARs (17% vs. 10%, ICIs and anticancer agents, respectively; p &amp;lt; .05). Mean times to onset were 47, 48, and 40 days (SJS, TEN, and DRESS, respectively), with comparable mean latency between monotherapy and combination regimens (41 days). This immune-related pattern advocates for long-lasting monitoring by oncologists and dermatologists.<\/jats:p>","DOI":"10.1634\/theoncologist.2019-0250","type":"journal-article","created":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T20:15:24Z","timestamp":1565122524000},"page":"e1228-e1231","source":"Crossref","is-referenced-by-count":41,"title":["Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System"],"prefix":"10.1093","volume":"24","author":[{"given":"Emanuel","family":"Raschi","sequence":"first","affiliation":[{"name":"Pharmacology Unit, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ippazio Cosimo","family":"Antonazzo","sequence":"additional","affiliation":[{"name":"Pharmacology Unit, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelangelo","family":"La Placa","sequence":"additional","affiliation":[{"name":"Dermatology Division, Department of Experimental, Diagnostic and Specialty Medicine, Policlinico S. Orsola-Malpighi, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ardizzoni","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Department of Experimental, Diagnostic and Specialty Medicine, Policlinico S. Orsola-Malpighi, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Poluzzi","sequence":"additional","affiliation":[{"name":"Pharmacology Unit, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"De Ponti","sequence":"additional","affiliation":[{"name":"Pharmacology Unit, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,8,6]]},"reference":[{"key":"2021122508050088200_onco13066-bib-0001","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918764628","article-title":"Clinical assessment of immune-related adverse events","volume":"10","author":"Sosa","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"2021122508050088200_onco13066-bib-0002","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"2021122508050088200_onco13066-bib-0003","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1634\/theoncologist.2018-0434","article-title":"Cases from the irAE Tumor Board: A multidisciplinary approach to a patient treated with immune checkpoint blockade who presented with a new rash","volume":"24","author":"Patil","year":"2019","journal-title":"The Oncologist"},{"key":"2021122508050088200_onco13066-bib-0004","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2016.02.010","article-title":"Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor","volume":"60","author":"Belum","year":"2016","journal-title":"Eur J Cancer"},{"key":"2021122508050088200_onco13066-bib-0005","doi-asserted-by":"crossref","DOI":"10.1177\/1758834017751634","article-title":"Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: Clinical features and management","volume":"10","author":"Shen","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"2021122508050088200_onco13066-bib-0006","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s11523-019-00632-w","article-title":"Toxicities with immune checkpoint inhibitors: Emerging priorities from disproportionality analysis of the FDA adverse event reporting system","volume":"14","author":"Raschi","year":"2019","journal-title":"Target Oncol"},{"key":"2021122508050088200_onco13066-bib-0007","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1634\/theoncologist.2018-0128","article-title":"A case of nivolumab-induced bullous pemphigoid: Review of dermatologic toxicity associated with programmed cell death protein-1\/programmed death ligand-1 inhibitors and recommendations for diagnosis and management","volume":"23","author":"Lopez","year":"2018","journal-title":"The Oncologist"},{"key":"2021122508050088200_onco13066-bib-0008","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1634\/theoncologist.2017-0511","article-title":"Anticancer agent-induced life-threatening skin toxicities: A database study of spontaneous reporting data","volume":"24","author":"Tanaka","year":"2019","journal-title":"The Oncologist"},{"key":"2021122508050088200_onco13066-bib-0009","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/clpt.2009.252","article-title":"ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: Comparison with case-control analysis","volume":"88","author":"Sassolas","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"2021122508050088200_onco13066-bib-0010","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejca.2019.01.015","article-title":"Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology","volume":"112","author":"Heinzerling","year":"2019","journal-title":"Eur J Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2019-0250","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2019-0250","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/11\/e1228\/41918120\/oncolo_24_11_e1228.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/11\/e1228\/41918120\/oncolo_24_11_e1228.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T08:06:15Z","timestamp":1640419575000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/24\/11\/e1228\/6439774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,6]]},"references-count":10,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2019,8,6]]},"published-print":{"date-parts":[[2019,11,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2019-0250","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,11,1]]},"published":{"date-parts":[[2019,8,6]]}}}